(OVID) Ovid Therapeutics Inc. Business Model Canvas Research

Ovid Therapeutics Inc. works with Northwestern University through a collaborative academic setup that supports translational science and early-stage research. These partnerships help sharpen target validation and disease biology work; Ovid’s latest SEC filings do not disclose a direct payment tied to this collaboration, so the value is mainly scientific, not near-term revenue.

• Supports early translational research
• Improves target validation quality
• Strengthens disease biology insights

Ovid Therapeutics Inc. and Marinus Pharmaceuticals, Inc. have a collaboration and licensing agreement focused on seizure and epilepsy research, which fits Ovid Therapeutics Inc.'s CNS pipeline strategy. The tie-up supports development work in overlapping neurological indications, where Marinus Pharmaceuticals, Inc.'s ganaxolone program has been studied in epilepsy and seizure disorders.

• Shared focus: seizure and epilepsy
• Supports overlapping CNS indications
• Backs development and licensing activity

OV882 is Ovid Therapeutics Inc. short hairpin RNA gene therapy candidate for Angelman syndrome, a rare disorder affecting about 1 in 15,000 births. This work needs vector design, delivery control, and safety testing, so it adds a higher-complexity path beyond Ovid Therapeutics Inc. small-molecule neuroscience pipeline.

• OV882 targets Angelman syndrome
• Requires vector and delivery expertise
• Broadens Ovid Therapeutics Inc. beyond small molecules

Ovid Therapeutics Inc. manages multiple alliances and licensing deals to fund its pipeline, tap outside science, and split development risk. For a small biopharma, this is core work: each deal can lower cash burn and keep programs moving without carrying the full cost alone.

• Funds research through partner capital
• Shares clinical and regulatory risk
• Expands access to external science

Clinical development infrastructure is a core resource for Ovid Therapeutics Inc., because Phase 2A and later work depends on tight protocol control, safety review, and clean regulatory reporting. As a development-stage biotech, Ovid’s value is tied to execution, not sales, so even one delayed trial can move timelines and cash use fast.

• Runs Phase 2A and later trials
• Manages safety and reporting
• Supports faster regulatory filings

Ovid Therapeutics Inc. is headquartered in New York, New York, and that single corporate base anchors management, financing, partnering, executive, and administrative work. One HQ keeps decision-making and partner outreach close to the leadership team.

• New York, New York headquarters
• Supports management and financing
• Anchors executive operations
• Central hub for partnering

Ovid Therapeutics Inc. targets rare pediatric and genetic brain disorders where care is thin: Fragile X syndrome, Angelman syndrome, tuberous sclerosis complex, and infantile spasms. These conditions affect roughly 1 in 4,000 males for Fragile X, 1 in 12,000-20,000 births for Angelman, about 1 in 6,000 for TSC, and 2-3 in 10,000 infants for spasms.

• Rare diseases, few approved options
• High unmet need for families
• Targets early-life neurological care

Ovid Therapeutics Inc. uses a partnered R and D model to pair in-house science with outside collaborators, which can shorten timelines and share clinical risk. For a small biotech, this matters because it helps fund and run multiple programs at once instead of betting on one asset.

• Shares R and D cost and risk
• Speeds development through partners
• Supports multiple programs at once

Ovid Therapeutics Inc. keeps research partner collaboration structured through shared R&D goals, data exchange, and licensing terms, which fits a long drug-development cycle. In fiscal 2025, the model still depended on external science and partner-led validation, so the value comes from lowering early-stage risk and spreading development costs across collaborators.

• Shared goals guide each program
• Data exchange speeds decisions
• Licensing sets economics
• Helps manage long timelines

Ovid Therapeutics Inc. uses scientific community outreach to keep research ties active, which helps build trust around its 0 marketed products and supports awareness of new data and trial openings. These interactions can speed informed feedback from clinicians and researchers, which matters in a company still driven by clinical-stage programs.

• Builds credibility with researchers and physicians
• Promotes trial awareness and data sharing
• Supports clinical-stage pipeline visibility

Ovid Therapeutics Inc. can use medical conferences and peer-reviewed journals to put trial data in front of clinicians, researchers, and investors fast; PubMed now indexes more than 38 million citations, so publication also boosts discoverability and credibility. In biotech, that matters because large meetings can draw thousands of specialists, while journal review adds a trusted filter before a result shapes practice or funding.

• Builds scientific credibility
• Reaches clinicians and researchers
• Supports investor confidence
• Improves data discoverability

As a public, pre-commercial biopharmaceutical company, Ovid Therapeutics Inc. uses earnings calls, SEC filings, press releases, and investor decks to reach capital markets and support financing. This channel matters most before product sales, when visibility and trust can shape access to equity funding.

Clear updates help explain pipeline progress, cash runway, and trial milestones, which investors use to judge dilution and timing risk.

• Reaches capital markets directly
• Supports funding before sales
• Explains trial and runway updates

Angelman syndrome affects about 1 in 12,000 to 20,000 people, and care is driven by lifelong needs for patients and caregivers. Ovid Therapeutics Inc. targets this rare-neurology group with OV882, a therapy designed for Angelman syndrome, making this segment a core focus of its pipeline.

• Rare genetic disorder
• Patients plus caregivers
• Core OV882 target

Epilepsy patients are Ovid Therapeutics Inc.’s core target for OV350, with focus on hard-to-control seizure burden in severe subgroups. Epilepsy affects about 50 million people worldwide, and roughly 30% remain drug-resistant, leaving a large unmet need for therapies that can cut seizure frequency and improve daily function.

• ~50 million global epilepsy patients
• ~30% drug-resistant cases
• OV350 aims at severe seizure control

Ovid Therapeutics Inc. carries public-company general and administrative expense for executive, legal, finance, compliance, and admin work, plus New York HQ overhead. In fiscal 2025, this line stayed a fixed operating burden that scales with reporting and governance needs, not with drug sales.

• Executive, legal, finance, compliance costs
• Public-company reporting overhead
• New York headquarters adds rent and support cost

This cost structure is typical for a small biotech with no product revenue, so G&A remains a key cash-use item in 2025.

Late-stage biopharma like Ovid Therapeutics Inc. has to fund process development, quality systems, and FDA prep before any approval. The FDA’s FY2026 New Drug Application fee is $4.32 million, and manufacturing readiness costs can rise fast as programs move toward launch.

• Process development starts before approval.
• Quality systems add fixed overhead.
• Regulatory fees can exceed $4M.

Ovid Therapeutics Inc. can earn royalties only if partnered assets reach market and sell well, so this is a back-ended biotech revenue stream. Royalties usually run as a small percentage of net sales, and in Ovid Therapeutics Inc.’s latest filings this line has remained tied to future commercial success, not current operating cash flow.

• Paid only after launch
• Depends on licensed sales
• Long-term, high-upside stream

Ovid Therapeutics Inc. has no approved products as of 2025, so future product sales are still a prospective revenue stream. If one candidate wins approval, direct product revenue would become the main commercial source for a fully launched therapy, but today this remains zero in the business model.

• No approved therapy yet
• Direct sales start only after approval